Formulary

8.2.2 Immunostimulants

First Line
Second Line
Specialist
Hospital Only

For immune globulins, please see section 14.2 Immunoglobulins

Interferons

Interferon alfa – 2a
  • Roferon-A pre-filled syringe
Interferon alfa – 2b
  • IntronA injection pen
  • IntronA injection
Interferon beta – 1a
  • Avonex pre-filled syringe
  • Rebif pre-filled syringe

Notes

  1. NICE TA527: Interferon beta-1a is recommended as an option for treating multiple sclerosis (MS) only if the person has relapsing-remitting MS, and the companies provide it according to commercial arrangements (June 2018) (NHS England Commissioned)
Interferon beta – 1b
  • Extavia injection

Notes

  1. NICE TA527: Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis (MS) only if the person has relapsing–remitting MS and has had 2 or more relapses within the last 2 years, or the person has secondary progressive MS with continuing relapses, and the company provides it according to the commercial arrangement (June 2018) (NHS England Commissioned)
  2. NICE TA527: Interferon beta‑1b (Betaferon) is not recommended as an option for treating MS (June 2018) (NHS England Commissioned)
Peginterferon alfa - 2a
  • Pegasys pre-filled pen
Peginterferon alfa – 2b
  • ViraferonPeg pre-filled pen

Notes

  1. NICE TA75: Peginterferon alfa, interferon alfa and ribavirin for chronic hepatitis C (January 2004)
  2. NICE TA106: Peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin (November 2007)
  3. NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part review of TA75 and TA106) (September 2010)
  4. NICE TA96: Peginterferon alfa-2a (February 2006)
  5. NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (November 2013)
Peginterferon beta - 1a
  • Plegridy solution for injection pre-filled pen 63micrograms in 0.5ml, 94micrograms in 0.5ml, 125micrograms in 0.5ml

Notes

  1. NICE TA624: Peginterferon beta‑1a (Plegridy) is recommended, within its marketing authorisation, as an option for treating relapsing–remitting multiple sclerosis in adults (February 2020)

Other immunostimulants

Glatiramer acetate
  • Copaxone injection

Notes

  1. NICE TA527: Glatiramer acetate is recommended as an option for treating multiple sclerosis (MS) only if the person has relapsing-remitting MS, and the company provides it according to the commercial arrangement (June 2018) (NHS England Commissioned)
Mifamurtide
  • IV infusion 4mg vial

Notes

  1. NICE TA235: Mifamurtide recommended for the treatment of osteosarcoma (October 2011)